A phase III study comparing the antiviral efficacy and safety of BMS-232632 [atazanavir] with efavirenz; each in combination with fixed dose zidovudine-lamivudine

Trial Profile

A phase III study comparing the antiviral efficacy and safety of BMS-232632 [atazanavir] with efavirenz; each in combination with fixed dose zidovudine-lamivudine

Completed
Phase of Trial: Phase III

Latest Information Update: 19 Dec 2006

At a glance

  • Drugs Atazanavir; Efavirenz; Lamivudine/zidovudine
  • Indications HIV infections
  • Focus Pharmacodynamics; Therapeutic Use
  • Sponsors Bristol-Myers Squibb
  • Most Recent Events

    • 19 Dec 2006 Status change
    • 13 Feb 2006 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top